- Home
- PLRX vs AUTL Comparison
PLRX vs AUTL Comparison
Compare PLRX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- AUTL
- Stock Information
- Founded
- PLRX 2015
- AUTL 2014
- Country
- PLRX United States
- AUTL United Kingdom
- Employees
- PLRX N/A
- AUTL N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLRX Health Care
- AUTL Health Care
- Exchange
- PLRX Nasdaq
- AUTL Nasdaq
- Market Cap
- PLRX 680.3M
- AUTL 590.8M
- IPO Year
- PLRX 2020
- AUTL 2018
- Fundamental
- Price
- PLRX $11.37
- AUTL $2.17
- Analyst Decision
- PLRX Strong Buy
- AUTL Strong Buy
- Analyst Count
- PLRX 7
- AUTL 3
- Target Price
- PLRX $40.50
- AUTL $10.20
- AVG Volume (30 Days)
- PLRX 485.5K
- AUTL 1.1M
- Earning Date
- PLRX 02-26-2025
- AUTL 03-13-2025
- Dividend Yield
- PLRX N/A
- AUTL N/A
- EPS Growth
- PLRX N/A
- AUTL N/A
- EPS
- PLRX N/A
- AUTL N/A
- Revenue
- PLRX N/A
- AUTL $10,091,000.00
- Revenue This Year
- PLRX N/A
- AUTL $851.83
- Revenue Next Year
- PLRX N/A
- AUTL $224.65
- P/E Ratio
- PLRX N/A
- AUTL N/A
- Revenue Growth
- PLRX N/A
- AUTL 82.71
- 52 Week Low
- PLRX $10.22
- AUTL $2.07
- 52 Week High
- PLRX $18.00
- AUTL $7.37
- Technical
- Relative Strength Index (RSI)
- PLRX 44.60
- AUTL 41.81
- Support Level
- PLRX $10.35
- AUTL $2.11
- Resistance Level
- PLRX $11.07
- AUTL $2.26
- Average True Range (ATR)
- PLRX 0.61
- AUTL 0.12
- MACD
- PLRX 0.06
- AUTL 0.01
- Stochastic Oscillator
- PLRX 43.50
- AUTL 27.78
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.